- Home
- UHG vs XGN Comparison
UHG vs XGN Comparison
Compare UHG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- XGN
- Stock Information
- Founded
- UHG 2004
- XGN 2002
- Country
- UHG United States
- XGN United States
- Employees
- UHG N/A
- XGN N/A
- Industry
- UHG Homebuilding
- XGN Medical Specialities
- Sector
- UHG Consumer Discretionary
- XGN Health Care
- Exchange
- UHG Nasdaq
- XGN Nasdaq
- Market Cap
- UHG 158.8M
- XGN 138.3M
- IPO Year
- UHG N/A
- XGN 2019
- Fundamental
- Price
- UHG $2.94
- XGN $7.07
- Analyst Decision
- UHG
- XGN Strong Buy
- Analyst Count
- UHG 0
- XGN 2
- Target Price
- UHG N/A
- XGN $7.50
- AVG Volume (30 Days)
- UHG 243.0K
- XGN 259.6K
- Earning Date
- UHG 08-07-2025
- XGN 08-04-2025
- Dividend Yield
- UHG N/A
- XGN N/A
- EPS Growth
- UHG N/A
- XGN N/A
- EPS
- UHG 0.76
- XGN N/A
- Revenue
- UHG $449,877,017.00
- XGN $56,724,000.00
- Revenue This Year
- UHG N/A
- XGN $18.92
- Revenue Next Year
- UHG N/A
- XGN $14.78
- P/E Ratio
- UHG $4.06
- XGN N/A
- Revenue Growth
- UHG 5.24
- XGN 1.78
- 52 Week Low
- UHG $1.60
- XGN $1.78
- 52 Week High
- UHG $6.93
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- UHG 48.24
- XGN 54.01
- Support Level
- UHG $2.71
- XGN $6.57
- Resistance Level
- UHG $2.95
- XGN $7.15
- Average True Range (ATR)
- UHG 0.35
- XGN 0.33
- MACD
- UHG -0.04
- XGN -0.04
- Stochastic Oscillator
- UHG 24.43
- XGN 61.73
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.